Azvudine in people with mild to moderate kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how the drug azvudine works in people with mild to moderate kidney disease compared to healthy people. It helps researchers understand if the dose needs to be adjusted for your kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- Your kidney function (GFR) is mildly to moderately reduced (between 30 and 89).
- Your kidney function has been stable for at least 3 months.
- You are not taking any medications that might interfere with the study drug, and you can keep a stable dose of your current medicines.
- You do not have liver problems (liver tests less than 1.5 times normal).
- You have not had a kidney transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies azvudine in adults with early COVID-19 symptoms to see if it can prevent the illness from getting severe. You may qualify if you’re within about 5 days of symptom start and have risk factors for worsening disease.
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
This early-phase study tests whether RVX000222 is safe and effective in people with end-stage kidney disease who receive hemodialysis. If you join, you’ll be carefully monitored to see how your body responds and whether it changes kidney-related health measures.
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
This trial tests a single dose of the study drug hydroxynidone in people with different levels of kidney function, including healthy volunteers and those with kidney disease. The goal is to learn how the drug works in the body when kidneys are not working normally.
Hear when a new Renal Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.